Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
来源：PubMed发布日期：2026-04-18作者：Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A0 次点击